Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Application Number 10519897 Filing Date 2004-12-31 First Named Inventor Ingemar Starke Art Unit 1624 Examiner Name Mark L. Berch Attorney Docket Number 133087.07001

				U.S.I	PATENTS		Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1	5306817		1994-04-26	Thiruvengadam et al.			
	2	5846966		1998-12-08	Rosenblum et al.			
	3	5767115		1998-06-16	Rosenblum et al.			
	4	5631365		1997-05-20	Rosenblum et al.			
	5	5739321		1998-04-14	Wu et al.			
	6	5886171		1999-03-23	Wu et al.			
If you wis	h to ac	dd additional U.S. Paten	t citatio	n information pl	ease click the Add button.	ı	Add	
			U.S.P	ATENT APPLIC	CATION PUBLICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Releva	Columns,Lines where nt Passages or Relevant s Appear	

Application Number		10519897
Filing Date		2004-12-31
First Named Inventor Ingem		nar Starke
Art Unit		1624
Examiner Name Mark		L. Berch
Attorney Docket Numb	er	133087.07001

	1							
If you wis	h to ac	dd additional U.S. Publi	shed Application	n citatio	n information p	please click the Add but	ton. Add	
			FOREIG	ON PAT	ENT DOCUM	ENTS	Remove	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> j	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T5
	1	0250060	WO		2002-06-27	Avantis Pharma Deutschland GMB		
	2	0250068	WO		2002-06-27	Aventis Pharma GMBH		
	3	0250027	WO		2002-06-27	Aventis Pharma GMBH		
	4	0218432	WO		2002-03-07	Aventis Pharma GMBH		
	5	02066464	WO		2002-08-29	Noda Atsushi et al.		
	6	524595	EP		1993-01-27	Schering Corporation		
	7	9414433	WO		1994-07-07	Schering Corporation		
	8	95/01961	wo		1995-01-19	Schering Corporation		

Application Number		10519897			
Filing Date		2004-12-31			
First Named Inventor	Ingen	nar Starke			
Art Unit		1624			
Examiner Name Mark		L. Berch			
Attorney Docket Numb	er	133087.07001			

9	9609827	wo	1996-04-04	Pfizer Inc.	
10	9745406	WO	1997-12-04	Schering Corporation	
11	0020623	WO	2000-04-13	Schering Corporation	
12	0034240	WO	2000-06-15	Schering Corporation	
13	0038725	WO	2000-07-06	G.D. Searle & Co.	
14	0060107	WO	2000-10-12	Schering Corporation	
15	0063703	WO	2000-10-26	Schering Corporation	
16	02072104	WO	2002-09-19	Merck & Co., Inc.	
17	02058685	WO	2002-08-01	Schering Corporation	
18	02058696	WO	2002-08-01	Schering Corporation	
19	02058731	WO	2008-08-01	Schering Corporation	

Application Number		10519897		
Filing Date		2004-12-31		
First Named Inventor	Ingen	nar Starke		
Art Unit		1624		
Examiner Name Mark		L. Berch		
Attorney Docket Numb	er	133087.07001		

	20	02058732	WO		2002-08-01	Schering Corporation			
	21	02058733	WO		2002-08-01	Schering Corporation			
	22	02058734	WO		2002-08-01	Schering Corporation			
	23	02079174	WO		2002-10-10	Schering Corporation			
	24	02096415	WO		2002-12-05	Schering Corporation			
	25	03026644	WO		2003-04-03	Schering Corporation			
If you wis	h to ac	dd additional Foreign P	atent Document	citation	information pl	ease click the Add buttor	Add Add		
			NON-PATEN	NT LITE	RATURE DO	CUMENTS	Remove		
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						<b>T</b> 5	
	1	Clader et al., "2-Azetidinone Cholesterol Absorption Inhibitors: Structure-Activity Relationships on the Heterocyclic Nucleus," J. Med Chem (1996) 39:3684-3693.							
	2	McKittrick et al., "Stereoselective synthesis and biological activity of cis azetidinones as cholesterol absorption inhibitors, Bioorganic & Medicinal Chemistry Letters (1996) 6(16):1947-1950.							
	3	Burnett et al., "2-Azetidinones as Inhibitors of Cholesterol Absorption," J. Med Chem (1994) 12:1733-1736.							

Application Number		10519897
Filing Date		2004-12-31
First Named Inventor Ingem		nar Starke
Art Unit		1624
Examiner Name Mark		L. Berch
Attorney Docket Numb	er	133087.07001

	4	Castaner et al., "Ezetimibe," Drugs of the Future (2000) 25(7):679-685.								
	5	Vaccaro et al., "Sugar-substituted 2-azetidinone cholesterol absorption inhibitors: Enhanced potency by modification of the sugar," Bioorganic & Medicinal Chemistry Letters (1998) 8:313-318.								
	6	Fu et al., "Process for preparing Ezetimibe intermediate by an acid enhanced chemo- and enantioselective CBS catalyzed ketone reduction," Tetrahedron Letters (2003) 44:801-804.								
	7	Kirkup et al., "(-)-SCH 57939: synthesis and pharmacological properties of a potent, metabolically stable cholesterol absorption inhibitor," Bioorganic & Medicinal Chemistry Letters (1996) 6(17):2069-2072.								
	8	Vaccaro et al., "Carboxy-substituted 2-azetidinones as cholesterol absorption inhibitors," Bioorganic & Medicinal Chemistry Letters (1998) 8:319-322.								
	9	Rosenblum et al., "Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4 - hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption.," J. Med Chem (1998) 41:973-980.								
	Wu et al., "A Novel One-Step Diastereo- and Enantioselective Formation of trans-Azetidinones and Its Application to the Total Synthesis of Cholesterol Absorption Inhibitors," J. Org. Chem (1999) 64:3714-3718.									
If you wis	h to ac	dd additional non-patent literature document citation information please click the Add button Add								
		EXAMINER SIGNATURE								
Examiner	Examiner Signature Date Considered									
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.										
Standard ST <sup>4</sup> Kind of doo	<sup>1</sup> See Kind Codes of USPTO Patent Documents at <u>www.USPTO.GOV</u> or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.									